Differential signaling by an anti-p185(HER2) antibody and heregulin

Xiao Feng Le, Ratna Vadlamudi, Amanda McWatters, Duk Soo Bae, Gordon Mills, Rakesh Kumar, Robert C. Bast

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

To understand the molecular mechanisms by which anti-p185(HER2) antibody and the ligand heregulin inhibit tumor growth, we have investigated several signaling proteins and pathways. We report here that anti-p185(HER2) monoclonal antibody ID5 induced tyrosine phosphorylation of HER2 in SKBr3 breast cancer cells that overexpress p185(HER2). Heregulin β1 induced phosphorylation of both HER3 and HER2. ID5 produced a greater association of phospholipase C (PLC)-γ1 with HER2 than did heregulin. Concordantly, ID5, but not heregulin, increased PLC-γ1 activity. However, the G1 cell cycle arrest and induction of p27(Kip1) produced by ID5 were not affected by the inhibition of PLC-γ. ID5 preferentially induced binding of the M(r) 46,000 isoform of SHC to HER2, whereas heregulin preferentially induced binding of the M(r) 52,00 isoform of SHC to HER3. Heregulin, but not ID5, induced the p85 subunit of phosphatidylinositol 3'-kinase (PI3-K) to interact with HER3. Heregulin induced sustained activation of PI3-K signaling, whereas ID5 had only a transient effect. Heregulin, but not ID5, activated the c-Jun-NH2- terminal kinase cascade. Pretreatment of SKBr3 cells with ID5 decreased heregulin-induced association of HER2 with HER3 as well as the activation of c-Jun-NH2-terminal kinase and PI3-K activities. Inhibition of the mitogen- activated protein kinase pathway in SKBr3 cells did not affect heregulin- induced G2-M-phase arrest, apoptosis, and differentiation. Heregulin-induced apoptosis could be blocked by inhibition of p70s6k, but not by inhibition of PI3-K. Heregulin-induced differentiation could be eliminated by inhibition of PI3-K. We conclude that ID5 and heregulin signal via different pathways, although both agents can inhibit the clonogenic growth of cells that overexpress HER2.

Original languageEnglish (US)
Pages (from-to)3522-3531
Number of pages10
JournalCancer Research
Volume60
Issue number13
StatePublished - Jul 1 2000
Externally publishedYes

Fingerprint

Neuregulin-1
Antibodies
Phosphatidylinositol 3-Kinase
Type C Phospholipases
JNK Mitogen-Activated Protein Kinases
Protein Isoforms
Phosphorylation
Apoptosis
70-kDa Ribosomal Protein S6 Kinases
G1 Phase Cell Cycle Checkpoints
G2 Phase
Growth
Mitogen-Activated Protein Kinases
Cell Division

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Le, X. F., Vadlamudi, R., McWatters, A., Bae, D. S., Mills, G., Kumar, R., & Bast, R. C. (2000). Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Research, 60(13), 3522-3531.

Differential signaling by an anti-p185(HER2) antibody and heregulin. / Le, Xiao Feng; Vadlamudi, Ratna; McWatters, Amanda; Bae, Duk Soo; Mills, Gordon; Kumar, Rakesh; Bast, Robert C.

In: Cancer Research, Vol. 60, No. 13, 01.07.2000, p. 3522-3531.

Research output: Contribution to journalArticle

Le, XF, Vadlamudi, R, McWatters, A, Bae, DS, Mills, G, Kumar, R & Bast, RC 2000, 'Differential signaling by an anti-p185(HER2) antibody and heregulin', Cancer Research, vol. 60, no. 13, pp. 3522-3531.
Le XF, Vadlamudi R, McWatters A, Bae DS, Mills G, Kumar R et al. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Research. 2000 Jul 1;60(13):3522-3531.
Le, Xiao Feng ; Vadlamudi, Ratna ; McWatters, Amanda ; Bae, Duk Soo ; Mills, Gordon ; Kumar, Rakesh ; Bast, Robert C. / Differential signaling by an anti-p185(HER2) antibody and heregulin. In: Cancer Research. 2000 ; Vol. 60, No. 13. pp. 3522-3531.
@article{ee00508df8684fd5a78a5a298cc97fca,
title = "Differential signaling by an anti-p185(HER2) antibody and heregulin",
abstract = "To understand the molecular mechanisms by which anti-p185(HER2) antibody and the ligand heregulin inhibit tumor growth, we have investigated several signaling proteins and pathways. We report here that anti-p185(HER2) monoclonal antibody ID5 induced tyrosine phosphorylation of HER2 in SKBr3 breast cancer cells that overexpress p185(HER2). Heregulin β1 induced phosphorylation of both HER3 and HER2. ID5 produced a greater association of phospholipase C (PLC)-γ1 with HER2 than did heregulin. Concordantly, ID5, but not heregulin, increased PLC-γ1 activity. However, the G1 cell cycle arrest and induction of p27(Kip1) produced by ID5 were not affected by the inhibition of PLC-γ. ID5 preferentially induced binding of the M(r) 46,000 isoform of SHC to HER2, whereas heregulin preferentially induced binding of the M(r) 52,00 isoform of SHC to HER3. Heregulin, but not ID5, induced the p85 subunit of phosphatidylinositol 3'-kinase (PI3-K) to interact with HER3. Heregulin induced sustained activation of PI3-K signaling, whereas ID5 had only a transient effect. Heregulin, but not ID5, activated the c-Jun-NH2- terminal kinase cascade. Pretreatment of SKBr3 cells with ID5 decreased heregulin-induced association of HER2 with HER3 as well as the activation of c-Jun-NH2-terminal kinase and PI3-K activities. Inhibition of the mitogen- activated protein kinase pathway in SKBr3 cells did not affect heregulin- induced G2-M-phase arrest, apoptosis, and differentiation. Heregulin-induced apoptosis could be blocked by inhibition of p70s6k, but not by inhibition of PI3-K. Heregulin-induced differentiation could be eliminated by inhibition of PI3-K. We conclude that ID5 and heregulin signal via different pathways, although both agents can inhibit the clonogenic growth of cells that overexpress HER2.",
author = "Le, {Xiao Feng} and Ratna Vadlamudi and Amanda McWatters and Bae, {Duk Soo} and Gordon Mills and Rakesh Kumar and Bast, {Robert C.}",
year = "2000",
month = "7",
day = "1",
language = "English (US)",
volume = "60",
pages = "3522--3531",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Differential signaling by an anti-p185(HER2) antibody and heregulin

AU - Le, Xiao Feng

AU - Vadlamudi, Ratna

AU - McWatters, Amanda

AU - Bae, Duk Soo

AU - Mills, Gordon

AU - Kumar, Rakesh

AU - Bast, Robert C.

PY - 2000/7/1

Y1 - 2000/7/1

N2 - To understand the molecular mechanisms by which anti-p185(HER2) antibody and the ligand heregulin inhibit tumor growth, we have investigated several signaling proteins and pathways. We report here that anti-p185(HER2) monoclonal antibody ID5 induced tyrosine phosphorylation of HER2 in SKBr3 breast cancer cells that overexpress p185(HER2). Heregulin β1 induced phosphorylation of both HER3 and HER2. ID5 produced a greater association of phospholipase C (PLC)-γ1 with HER2 than did heregulin. Concordantly, ID5, but not heregulin, increased PLC-γ1 activity. However, the G1 cell cycle arrest and induction of p27(Kip1) produced by ID5 were not affected by the inhibition of PLC-γ. ID5 preferentially induced binding of the M(r) 46,000 isoform of SHC to HER2, whereas heregulin preferentially induced binding of the M(r) 52,00 isoform of SHC to HER3. Heregulin, but not ID5, induced the p85 subunit of phosphatidylinositol 3'-kinase (PI3-K) to interact with HER3. Heregulin induced sustained activation of PI3-K signaling, whereas ID5 had only a transient effect. Heregulin, but not ID5, activated the c-Jun-NH2- terminal kinase cascade. Pretreatment of SKBr3 cells with ID5 decreased heregulin-induced association of HER2 with HER3 as well as the activation of c-Jun-NH2-terminal kinase and PI3-K activities. Inhibition of the mitogen- activated protein kinase pathway in SKBr3 cells did not affect heregulin- induced G2-M-phase arrest, apoptosis, and differentiation. Heregulin-induced apoptosis could be blocked by inhibition of p70s6k, but not by inhibition of PI3-K. Heregulin-induced differentiation could be eliminated by inhibition of PI3-K. We conclude that ID5 and heregulin signal via different pathways, although both agents can inhibit the clonogenic growth of cells that overexpress HER2.

AB - To understand the molecular mechanisms by which anti-p185(HER2) antibody and the ligand heregulin inhibit tumor growth, we have investigated several signaling proteins and pathways. We report here that anti-p185(HER2) monoclonal antibody ID5 induced tyrosine phosphorylation of HER2 in SKBr3 breast cancer cells that overexpress p185(HER2). Heregulin β1 induced phosphorylation of both HER3 and HER2. ID5 produced a greater association of phospholipase C (PLC)-γ1 with HER2 than did heregulin. Concordantly, ID5, but not heregulin, increased PLC-γ1 activity. However, the G1 cell cycle arrest and induction of p27(Kip1) produced by ID5 were not affected by the inhibition of PLC-γ. ID5 preferentially induced binding of the M(r) 46,000 isoform of SHC to HER2, whereas heregulin preferentially induced binding of the M(r) 52,00 isoform of SHC to HER3. Heregulin, but not ID5, induced the p85 subunit of phosphatidylinositol 3'-kinase (PI3-K) to interact with HER3. Heregulin induced sustained activation of PI3-K signaling, whereas ID5 had only a transient effect. Heregulin, but not ID5, activated the c-Jun-NH2- terminal kinase cascade. Pretreatment of SKBr3 cells with ID5 decreased heregulin-induced association of HER2 with HER3 as well as the activation of c-Jun-NH2-terminal kinase and PI3-K activities. Inhibition of the mitogen- activated protein kinase pathway in SKBr3 cells did not affect heregulin- induced G2-M-phase arrest, apoptosis, and differentiation. Heregulin-induced apoptosis could be blocked by inhibition of p70s6k, but not by inhibition of PI3-K. Heregulin-induced differentiation could be eliminated by inhibition of PI3-K. We conclude that ID5 and heregulin signal via different pathways, although both agents can inhibit the clonogenic growth of cells that overexpress HER2.

UR - http://www.scopus.com/inward/record.url?scp=0034235598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034235598&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 3522

EP - 3531

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -